Filing Flows › Maxcyte (MXCT) › Q1 2026
Maxcyte (MXCT) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 13, 2026
Maxcyte (MXCT) reported revenue of $9.7M for the first quarter 2026 (Q1 2026), -7% from a year earlier and +32% from the quarter before. Operating margin was -64.1%, net loss $4.8M (49.2% of revenue).
Maxcyte, Q1 2026: revenue $9.7M (-7% year over year), operating margin -64.1%, net loss $4.8M, operating cash flow −$8.2M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $9.7M | +32% | -7% |
| Operating profit | −$6.2M | — | — |
| Net earnings | −$4.8M | — | — |
| Operating cash flow | −$8.2M | — | — |
What changed
Revenue was $9.7M in Q1 2026, down 7% year over year and up 32% from the previous quarter. Licenses was the largest line at 57% of revenue. Product sales lost $1.7M year over year (down 32%), 227% of the total change.
Gross margin was 83.7%, down 1.8 points from Q1 2025. Operating costs exceeded revenue by $6.2M, an operating margin of -64.1%. Operating expenses fell 33% while revenue fell 7%. The quarter ended with a net loss of $4.8M, narrower than the previous quarter's $9.6M loss. Non-operating items added $1.4M, -30% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$8.2M. Non-cash charges added back $1.0M of depreciation and amortization and $1.1M of share-based compensation. Working capital and other items used $5.6M. Capital expenditures of $72K exceeded it, leaving free cash flow of −$8.2M.
Questions
What was Maxcyte's revenue in the first quarter 2026?
Maxcyte (MXCT) reported revenue of $9.7M for the first quarter 2026 (Q1 2026), -7% from a year earlier and +32% from the quarter before.
Was Maxcyte profitable in the first quarter 2026?
Operating loss was $6.2M (-64.1% of revenue) and net loss $4.8M.
Source: Maxcyte 10-Q on SEC EDGAR.